Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Siemens, takes on Prowess DAO tech

This article was originally published in Clinica

Executive Summary

Siemens Healthcare has teamed up with radiotherapy company Prowess in a bid to develop new radiation oncology treatment planning software. The exclusive partnership will see Siemens integrate into its linear accelerators Prowess' direct aperture optimisation (DAO) technology. The DAO technology allows clinicians to make on-line corrections to the treatment plan based on pre-treatment CT scans, just before the patient is about to receive therapy. This combination is designed to help users reduce the amount of equipment in the workplace and cut down overall treatment times. Chico, California-based Prowess is currently developing the DAO-based Plan-to-Patient software for radiation therapy, which is undergoing clinical assessment and is scheduled to become commercially available in Q2 2008. According to Siemens, the Plan-to-Patient device works in conjunction with its CTVision system, an image-guided radiation therapy device.

You may also be interested in...



Mylan Weighs In On Coronavirus Drug Shortage Concerns

Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business. 

 

Eyes On Pricing As Zolgensma Moves Closer To Japan Market

Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.

QUOTED. 28 February 2020. Jubilee Brown.

Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.

Topics

UsernamePublicRestriction

Register

MT046228

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel